The negative experience of somatostatin synthetic analogist using in therapy of policystoc ovaries

Abstract

The blood content of insulin—like growth factor—1 (IGF—1) in woman with ovarian hyperstimulation syndrome (OHSS) is low that may be connect with damage of synthetic function of liver. The use of synthetic analogist of somatostatin in treatment of OHSS don’t lead to reliable positive results. Low content of IGF—1 in OHSS makes pathogeneticaly non—justifight the treatment of OHSS by synthetic analogist of somatostatin.

Keywords

ovarian hyperstimulation syndrome (OHSS) / insulin—like growth factor—1 (IGF—1) / somatostatin / induction of ovulation

References

[1] Schenker J.G., Weinstein D. // Fertile Steril. — 1978. — Vol. 30.—P. 255—268.

[2] Delvigne A., Rosenberg S. Epidemiology and prevention of ovarian hyperstimulashion syndrome (OHSS): a review // Human Reprod. Update.—2002.—Vol. 8 (6).—P.559—577.

[3] Forsdahl F., Holst N., Tollan D. et al. Transcapillary fluid dynamics during ovarian stimulashion for in vitro fertilization // Am. J. Obstet. Gynecol.— 1990.—Vol. 162.—P. 554—8.

[4] Dominguez C.E. et al. Increased capillary permeability induced by human follicular fluid a hypothesis for an ovarian origin of the hyperstimulation syndrome (see comments) // Fertil Steril.—1995.—Vol. 63.—P. 268—72.

[5] Baumgardner G.P. et al. Ovarian hyperstimulashion syndrome pre—ovulatry serum concentrations of interleiukin— 6, interleukin—1, receptor antagonist and tumor necrosis factor—alfa cannot predict its occurrence // Human Reprod.—1996.—Vol. 11.—P. 1377—80.

[6] Abramov Y., Lewin A., Schenker J.D. et al. Plasma inflammatory cytokines correlate to the ovarian hyperstimulahaion syndrome // Human Reprod. — 1996. — Vol. 11.—P. 1381—6.

[7] Knox J.E. Antigistamin blockade of the ovarian hyperstimulastion syndrome // Am. J .Obstet. Gynecol. — Vol. 118.—Р. 992—4.

[8] Spiesil S.A., Knox G.E., Dowd A.J. et al. Antigistamine blocade of the ovarian hyperstimulahaion syndrome. II. Possible role of antigen—antibody complexes in the pathogenesis of the syndrome // Fertil. Steril.—Vol. 26.—P. 418—21.

[9] Gergely R.Z., Paldy E., Erlic Y. et al. Treatment of ovarian hyperstimulashion syndrome by antihistamine // Ostet. Gynecol.—1976.—Vol. 47.—P. 83—5.

[10] Erlic Y., Polishuk W.Z., Schencer J.G. The role of prostaglandine in ovarian hyperstimulation syndrome // Eur. J. Obstet. Gynecol. Reprod. Biol.—1976.— Vol. 6.—P. 47—52.

[11] Moon Y.S., Pride S.M.,Yuen B.H., et al. Relationship of gonadotropin—releasing hormone, danazol, and prostaglandin blocade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit // Am. J. Obstet. Gynecol.—1986.—Vol. 154.—P. 1155—60.

[12] Healy D.L., McClure N., Rogers P.A. et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulataion syndrome // Lancet.—1994. — Vol. 344.—P. 235—6.

[13] Berga S.L., Guzick D.S., Krasnov J.S. et al. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulataion syndrome: a preliminary report // Fertil. Steril.—1996.—Vol. 65.—P. 552—5.

[14] Abramov Y., Barac V., Nisman b.., et al. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulataion syndrome // Fertil. Steril.—1997.—Vol. 67.—P. 261—5.

[15] Christenson L.K., Lee A., Stouffer R.L. Vascular endothelial growth factor levels in serum and follicule fluid of patients undergoing in vitro fertilization // Fertil. Steril.—1997.—Vol. 68.—P. 305—1.

[16] MacDougall M.J., Jacobs H.S., Tan S.L. In—vitro fertilization and the ovarian hyperstimulataion syndrome // Human Reprod.—1992.—Vol. 7.—P. 597—600.

[17] Buyalos R.P., Lee C.T. Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization // Fertil. Steril.—1996.—Vol. 65.—P. 1—10.

[18] Lidor A., Soriano D., Seidman D.S. et al. Combined somatostatin analog and follicle—stimulating hormone for women with polycystic ovary syndrome resistant to conventional treatment // Gynecol. Endocrinol.—1998.—Vol. 12 (2).—P. 97—101.

[19] Carmina E., Morris R.S., Vijod M.A. et al. Alterations in the sensitivity of serum insulin—like growth factor 1 and insulinlike growth factor binding protein—3 to octreotide in polycystic ovary syndrome // Fertil. Steril.—1995.—Vol. 63 (4).—p. 742—6.

[20] de Boer J.A., Hompes P.G., van der Meer M. et al. Octreotide, a somatostain analogue, alters ovarian sensitivity to gonadotrophin stimulation as measured by the follicle stimulation hormone threshold in polycystic ovary syndro—me // Human Reprod. — 1998. — Vol. 13(6).—P. 1465—9.

[21] Denburg M.R., Manibo A.M., Silfen M.E. et al. Early endocrine, metabolic and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents // Clin. Endocrinol. Metab.—2003.—Vol. 88(10).—P. 4682—8.

[22] Dragojevic S., Prorocic M., Vasiljevic M. et al. The role of insulin—like growth—factor binding proteins in normal and polycystic ovaries // Srp. Arh. Celoc. Leс. —1998. — Vol. 126 (11—12).—P. 488.

[23] Iwashita M., Mimuro T., Watanabe M. et al. Plasma level of insulin—like growth factor 1 and its binding protein in polycystic ovary syndrome // Horm. Res.—1990.—Vol. 33.—P. 21—6.

[24] Gordana M., Prevelic M.I., Wurzburger et al. Effects of the Somatostatin Analogue, Octreotide, in polycystic ovary syndrome. // Metabolizm. — 1992.— Vol. 41.— P. 76—79.

[25] Morris R.S., Vishvanath C., Karande et al. Octreotida is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome // Fertil. Steril. — 1999. — Vol. 71(3).—P. 452—456.

[26] Shenker J.G. Ovarian hyperstimulation syndrome // In: Reproductive Medicine and Surgery.— 1995. — P. 650_679

RIGHTS & PERMISSIONS

Eсо-Vector